Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2023
TGA commences evaluation of Moderna COVID-19 vaccine (Spikevax) for potential transition to full registration
20 January 2023 - The TGA has commenced evaluation of an application from Moderna to transition its COVID-19 vaccine, Spikevax, ...
Posted by Michael Wonder on 21 Jan 2023
Novartis warns US plan to curb drug prices could hit key research
21 January 2023 - US Government plans to rein in drug prices could discourage work in some of Novartis' most ...
Posted by Michael Wonder on 20 Jan 2023
UK's voluntary scheme for branded medicines, pricing and access (VPAS) faces a potential crisis
19 January 2023 - The UK has a “voluntary scheme for branded medicines, pricing, and access” or VPAS, which sets a ...
Posted by Michael Wonder on 18 Jan 2023
FDA’s breakthrough program: faster drug OKs without sacrificing safety
18 January 2023 - A FDA program markedly cut the time and cost of bringing to market new drugs, without ...
Posted by Michael Wonder on 18 Jan 2023
Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi (amifampridine) following a favourable Canadian Federal Court of Appeal ruling
17 January 2023 - Medunik Canada is pleased to announce that on 9 January 2023, the Federal Court of Appeal of ...
Posted by Michael Wonder on 16 Jan 2023
A new US law aims to reduce drug prices. But first, it might raise them.
14 January 2023 - A new US law meant to blunt drug prices could reduce pharmaceutical-company revenue by about $40 billion ...
Posted by Michael Wonder on 16 Jan 2023
AbbVie and Eli Lilly, two of the world’s largest pharmaceutical companies, have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks
16 January 2023 - AbbVie and Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access, a ...
Posted by Michael Wonder on 16 Jan 2023
The game-changing plan to cut barriers to medical abortion
16 January 2023 - A push is under way to make medical abortion more accessible across Australia by cutting down ...
Posted by Michael Wonder on 15 Jan 2023
US to announce list of drugs for pricing negotiations 1 September
12 January 2023 - The US Government will announce a list of 10 prescription drugs for which it plans to ...
Posted by Michael Wonder on 13 Jan 2023
Recent patent reform bills and their implications for prescription drugs
13 January 2022 - In 2022, several bills were introduced in Congress to revamp US intellectual property law. ...
Posted by Michael Wonder on 13 Jan 2023
As CMS asks for the public’s feedback on implementing the Inflation Reduction Act, unresolved issues related to drug price negotiations remain
11 January 2022 - On 11 January, the Centers for Medicare and Medicaid Services (CMS) announced a timeline for implementation of ...
Posted by Michael Wonder on 12 Jan 2023
Intellia Therapeutics awarded Innovation Passport in the United Kingdom for NTLA-2002, an investigational genome editing treatment for hereditary angioedema
11 January 2023 - NTLA-2002 is a single dose genome editing therapeutic candidate designed to prevent angioedema attacks in people ...
Posted by Michael Wonder on 10 Jan 2023
US Supreme Court rebuffs Pfizer plan to help patients pay for heart medication
9 January 2023 - The US Supreme Court on Monday turned away Pfizer's bid to revive its plan to cover ...
Posted by Michael Wonder on 10 Jan 2023
Pharmacy benefit managers and the Federal Trade Commission: a relationship gone sour
9 January 2023 - On 7 June 2022, the Federal Trade Commission announced its decision to launch an inquiry into the ...
Posted by Michael Wonder on 10 Jan 2023
Four types of bias in medical AI are running under the FDA’s radar
9 January 2023 - Although artificial intelligence is entering health care with great promise, clinical artificial intelligence tools are prone ...